Pilot study for surgery and new medicine in recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This early study looks at a treatment plan (including resection/surgery and an added medicine) for glioblastoma that has come back after standard therapy. The goal is to see how well it controls tumor growth and whether it is tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to join the study by signing consent before any study procedures.
- You are age 18 or older and have confirmed IDH-wild type glioblastoma that has grown back for the first or second time after radiation and temozolomide.
- Your doctors must think the recurrent tumor can be surgically removed (resection).
- You must be able to handle study check-ins and brain MRIs, and you should be well enough to be classed as ECOG 0–2.
- If you can become pregnant: you must have a negative pregnancy test and use two highly effective birth-control methods during the study and for up to 180 days after the last dose.
- You should not have key health problems (for example heart pumping function too low, major liver/kidney blood test abnormalities, lung scarring/ILD, significant ECG QTc issues, active hepatitis B/C or HIV, or ongoing diarrhea due to bowel disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial compares surgery to the best non-surgical treatment for people whose glioblastoma has come back. The goal is to see which approach helps people live longer with a better quality of life.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.